ContributorsPublishersAdvertisers

Cilta-cel Produced Durable Responses, Manageable Safety Profile for Relapsed/Refractory Multiple Myeloma

cancernetwork.com
 2021-10-11

The phase 1b/2 CARTIRUDE-1 study found deep and durable responses, along with a tolerable safety profile with the recommended phase 2 dose of ciltacabtagene autoleucel for patients with relapsed or refractory multiple myeloma. Early, deep, and durable responses and a manageable safety profile were observed with a single infusion...

www.cancernetwork.com

Comments / 0

Comments / 0